Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis
Hao Yan(ZheJiang Institute For Food and Drug Control), Peihua Luo(Zhejiang Lab)
Cited by 39
Related Papers
A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
|Frontiers in Pharmacology|2020|80
Formononetin protects against cisplatin‑induced acute kidney injury through activation of the PPARα/Nrf2/HO‑1/NQO1 pathway
|International Journal of Molecular Medicine|2020|65
Inhibition of PRKAA/AMPK (Ser485/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion
|Autophagy|2023|56